Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Codiak BioSciences

Biogen Idec building

Biogen’s tofersen shows promise in slowing down ALS

Hope for subset of patients with wasting disease

- PMLiVE

Biogen’s Spinraza overpriced, says ICER

Cost watchdog warns high price puts pressure on US health system

- PMLiVE

Biogen and Eisai pull plug on Alzheimer’s drug

Further undermines amyloid-targeting approach

Biogen Idec building

Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022

Also considering a trial in preclinical Alzheimer’s subjects

Biogen Idec building

Biogen strikes $800m deal to buy gene therapy firm Nightstar

Will also acquire CHM candidate and a therapy for XLRP

Biogen Idec building

FDA starts review of Biogen’s Tecfidera follow-up for MS

It was initally submitted towards the end of 2018 but had been delayed by US gov shutdown

- PMLiVE

Biogen files Tecfidera follow-up in the US

Improved GI tolerability is major selling point

- PMLiVE

Biogen picks up another drug from wide-ranging Ionis alliance

Aims to follow success of Spinraza

- PMLiVE

FDA fast tracks Novartis’ SMA gene therapy

Gene therapy could be approved in first half of 2019, will challenge Biogen's Spinraza

- PMLiVE

Spinraza lifts Biogen ahead of Alzheimer’s data

Continued strong growth for Biogen’s spinal muscular atrophy therapy Spinraza helped the company exceed revenue expectations in the third quarter, but pipeline disappointments kept its shares largely static.Spinraza (nusinersen) was...

- PMLiVE

Shock as NICE turns down Biogen’s SMA therapy

UK’s cost effectiveness watchdog says the drug’s long-term benefits are unclear

Biogen Idec building

Big debate follows Biogen/Eisai’s Alzheimer’s study unveiling

Mixed results prompted a 10% share drop for both companies

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links